Teacher Retirement System of Texas Buys 5,118 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Teacher Retirement System of Texas increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 18.3% during the fourth quarter, Holdings Channel reports. The firm owned 33,154 shares of the biotechnology company’s stock after acquiring an additional 5,118 shares during the period. Teacher Retirement System of Texas’ holdings in Arrowhead Pharmaceuticals were worth $623,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Intech Investment Management LLC bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at about $659,000. Charles Schwab Investment Management Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company’s stock worth $19,504,000 after acquiring an additional 12,574 shares in the last quarter. Quantbot Technologies LP bought a new position in Arrowhead Pharmaceuticals in the third quarter valued at approximately $149,000. BNP Paribas Financial Markets raised its position in Arrowhead Pharmaceuticals by 40.1% during the third quarter. BNP Paribas Financial Markets now owns 55,188 shares of the biotechnology company’s stock valued at $1,069,000 after purchasing an additional 15,784 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Arrowhead Pharmaceuticals by 5.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,262 shares of the biotechnology company’s stock worth $586,000 after purchasing an additional 1,523 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ARWR shares. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. B. Riley reissued a “buy” rating and issued a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $41.44.

Arrowhead Pharmaceuticals Trading Up 0.1 %

ARWR opened at $13.82 on Monday. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $13.66 and a fifty-two week high of $30.41. The company’s 50 day moving average price is $18.13 and its two-hundred day moving average price is $19.60. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -2.67 and a beta of 0.92.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). As a group, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Activity

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 27,167 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.83, for a total transaction of $538,721.61. Following the sale, the chief financial officer now owns 473,433 shares of the company’s stock, valued at approximately $9,388,176.39. This represents a 5.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher Richard Anzalone sold 11,520 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the transaction, the chief executive officer now directly owns 3,764,252 shares of the company’s stock, valued at approximately $71,709,000.60. This trade represents a 0.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 286,317 shares of company stock valued at $5,049,735. Company insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.